PPAR alpha Antibody - #AF5301

Fig. 9 The nuclear transcription factor PPARα mediates T2D-induced specific reduction in the expression of osteocytic SERCA2 pump. a RNA-seq-based KEGG pathway analysis showing the top 10 enriched KEGG pathways. b, c GSEA analysis showing a significant enrichment of signaling events associated with PPARα and PPARDR1_Q2. d The PPARα and p-PPARα protein expression in osteocytes. e Immunohistochemical staining of osteocytic PPARα in diabetic and non-diabetic tibiae. f The SERCA2 expression in osteocytes treated with antagonists of PPARα (MK886 and GW6471), PPARβ/δ (GSK0660 and GSK3787), and PPARγ (T0070907 and GW9662). g The SERCA2 expression in HGHF-exposed osteocytes treated with agonists of PPARα (Fenofibrate and GW7647), PPARβ/δ (GW0742 and GW501516), and PPARγ (rosiglitazone and pioglitazone). h A schematic representation and the relative luciferase activities of three ATP2A2 promotor regions. i The relative luciferase activity assays of Seg#1, Seg#2 and Seg#3. j The relative luciferase activity in HGHF-treated osteocytes with PPARα silencing. k ChIP assays showing the PPARα enrichment on ATP2A2 promotor in normal and HGHF-treated osteocytes. l EMSA assays confirming the binding of PPARα to the ATP2A2 promoter region (−620 to −608 bp). The nuclear extract were incubated with biotin-labeled wild-type (WT-biotin) probe, unlabeled wild-type (WT) probe, and biotin-labeled mutated (Mut-biotin) probe. Red letters indicate substituted nucleotide sequences in the mutated probes (P1: −620 to −608 bp; P2: −1283 to −1277 bp). m, n Intracellular Ca2+ signaling and protein expression of osteocyte-related cytokines in HGHF-treated osteocytes with PPARα overexpression subjected to FSS. o, p Intracellular Ca2+ signaling and the expression of osteocyte-related cytokines in MLO-Y4 cells with lentiviral silencing of PPARα subjected to FSS. Graphs represent mean ± SD (d, f, g, i–k, m, o n = 6 biologically independent replicates; e n = 8 mice per group; l n = 3 independent replicates; n, p: n = 120 cells per group). a P value was obtained by one-tailed hypergeometric test. b, c P values were obtained by one-tailed permutation test. d–h, n, p ***P 

Fig. 6. β-PAE promotes the expression of hepatic lipid oxidation-related proteins and genes in HFD-fed rats. (A–G) Western blot analysis on the expression of SIRT1, PGC-1α, PPARα, FGF21, CPT-1a and ACOX1; (H–K) The mRNA expression of SIRT1, PPARα, CPT-1a and ACOX1. Data are presented as the mean ± SD (n = 6~8). ##p < 0.01 vs. NC group; *p < 0.05, **p < 0.01 vs. Model group.

Fig. 5. Effects ofL. plantarum Q16 on key proteins involved in hepatic lipid metabolism in HFD-fed obese mice. Data are presented as mean ± SD (n = 6). Different lowercase alphabet letters were significantly different at the level of P < 0.05.

Fig. 5 The effects of different diets on muscle protein synthesis and lipolysis of grass carp. (A) Protein synthesis related gene expression; (B) lipolysis-related gene expression; (C) Western blot analysis of p-AMPK, AMPK, PPARα, TOR, p70S6K, PI3K, and AKT protein expression; (D) relative quantification of p-AMPK, PPARα, TOR, p70S6K, PI3K, and AKT protein expression. The bars indicate the mean ± standard error (SE). Different superscripts denote significant differences (P < 0.05). CON = a control group (containing 4.95% crude fat); HFD = a high fat diet (containing 10.27% crude fat); HFDS = supplementing 1200 μg/kg sanguinarine to HFD.

FIGURE 5 EPC regulated the lipid metabolism-related genes and proteins inMAFLD rats. (A) mRNA abundances of FASN. (B) mRNA abundances of PPARα (PPARΑ). (C) mRNA abundances of PPARγ (PPARG). (D) mRNA abundances of RXRα. (E) mRNA abundances of CYP19A1. (F) mRNA abundances of NR3C1. (G) mRNA abundances of SREBP-1c. (H) mRNA abundances of HMGCR. (I) mRNA abundances of SCD. n = 6; (J) Relative expression of protein SCD. (K) Relative expression of protein PPARα. (L) Relative expression of protein FASN. (M) Relative expression of protein p-JNK. (N) Relative expression of protein p-NF-κB. (O) Relative expression of protein CYP19A1. (P) Relative expression of protein NR3C1. (Q-R) Representative immunoblotting images of β-actin, SCD, PPARα, FASN,CYP19A1, NR3C1, JNK, p-JNK, NF-κB, pNF-κB; n = 4, data are presented as mean ± SEM. One-way analysis of variance (ANOVA) was conducted for the group comparison. *p < 0.05, **p < 0.01, ***p < 0.001 vs MOD group. FASN, fatty acid synthase; PPARα/γ, peroxisome proliferator-activated receptor alpha/gamma; RXRa, retinoic acid receptor alpha; SREBP-1c, sterol regulatory element binding protein 1c; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; SCD, Stearoyl-CoA desaturase; p-JNK, phosphorylation (p) -stress-activated protein kinase JNK; NF-κB, nuclear factor kappa B.